Pattern of metastasis and outcome in patients with XXXX .

@entity1722 @entity0 @entity1349 @entity10204
UNASSIGNED: There is growing evidence about differences in metastatic spread among @entity0 ( @entity0 ) @entity10204 ( @entity10204 ). Aim of this study was to analyze the pattern of metastasization according to @entity10204 and to explore the corresponding prognosis. A series of 544 consecutive patients receiving anticancer therapy for metastatic @entity0 from 2004 to 2013, was analyzed. @entity10204 were defined by immunohistochemistry according to St Gallen 2013 criteria. Association between @entity10204 and the different distant localizations was analyzed. Prognosis was described in terms of overall survival (OS), progression free survival (PFS) and @entity1349 ( @entity1349 ). Results were reported taking luminal A @entity0 as reference. Triple negative @entity0 showed a higher tropism for lung (OR 4.30 95  % CI 1.41-13.1), while non luminal @entity1722 subtype was associated with a higher rate of liver metastases (OR 3.61 95  % CI 1.36-9.58). All subtypes were associated with a lower risk of bone-only localization. Central nervous system (CNS) involvement was more common in @entity1722 positive @entity0 (OR 6.3, 95  % CI 1.08-36.66). Liver, lung and CNS involvement influenced negatively OS (HR 1.64, 95  % CI 1.29-2.07; HR 1.49, 95  % CI 1.18-1.90; HR 2.891, 95  % CI 1.85-4.51, respectively) and PFS (HR 1.39, 95  % CI 1.13-1.71; HR 1.26, 95  % CI 1.02-1.55; HR 1.75, 95  % CI 1.12-2.71, respectively). Multivariate analysis confirmed liver involvement as independent predictor of worse OS (HR 1.64, 95  % CI 1.15-2.34). Stratification by metastatic pattern showed significant differences in terms of @entity1349 but not in terms of PFS. The study suggests that @entity10204 may be characterized by typical patterns of metastatic spread and have different impact on clinical outcome.
